Patients taking Kerendia saw significant reduction in cardiovascular death and hospitalization and urgent visits for heart ...

The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.

The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.

The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.

Heart failure occurs when the heart muscle does not pump blood as well as it should. Heart failure symptoms can sometimes be ...

Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...

Heart failure, a leading cause of death in the US, can be triggered by cardiac amyloidosis, a condition often misdiagnosed as ...

The use of SGLT2 inhibitors has been a game-changer in the treatment of heart failure (HF). Now, another drug class has ...

Micah Clayborne was diagnosed with Danon disease, a rare condition, after complaining of chest pains. He needed a heart ...

Wearables and telehealth are teaming up to transform chronic care. This connected model offers real-time data for proactive, ...

Discover how MemorialCare's Women's Heart Center at Long Beach is tackling the leading killer of women, heart disease, ...